Compare PLSE & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | RLAY |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2015 | 2020 |
| Metric | PLSE | RLAY |
|---|---|---|
| Price | $25.37 | $8.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $22.00 | $15.75 |
| AVG Volume (30 Days) | 404.9K | ★ 2.3M |
| Earning Date | 05-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.41 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,007,000.00 |
| Revenue This Year | N/A | $19.96 |
| Revenue Next Year | $1,250.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.56 | $1.78 |
| 52 Week High | $26.30 | $9.54 |
| Indicator | PLSE | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 71.93 | 55.85 |
| Support Level | $22.93 | $8.81 |
| Resistance Level | $25.80 | $9.54 |
| Average True Range (ATR) | 2.17 | 0.63 |
| MACD | 0.78 | 0.05 |
| Stochastic Oscillator | 91.60 | 67.22 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).